Compare Ginkgo Bioworks Holdings Inc (DNA) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 16.5× Ginkgo Bioworks Holdings Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| DNA | HALO | |
|---|---|---|
Market Cap | $763.64M | $12.58B |
Volume | 3,204,177 | 2,179,278 |
Sector | Health | Health |
52-Week High | $15.83 | $115.22 |
52-Week Low | $5.48 | $61.63 |
Typical Hold Time | 7 Days | 1 Days |
Enterprise Value | $865.59M | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
